Probatebeta
Target

PDE4B

3',5'-cyclic-AMP phosphodiesterase 4B

As of the edition of 20 October 2026, PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B, UniProt Q07343) has 26 drugs tested at it and 21 companies on the list, 7 on route A and 7 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q07343
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
41
Disease areas
Skin and connective tissue; Lungs and airways; Immune system; Inherited and neonatal; Bones, joints and muscles; Nervous system; Infections; Nutrition and metabolism
Registered trials of its drugs
475

Drugs at this target

StatusCount
Marketed13
Active1
Went quiet8
Stopped3
Status not established1
Total26
DrugStatusFurthest phaseUS protection
ApremilastMarketedPhase 4Ends 2028
RoflumilastMarketedPhase 4none listed
Theophylline anhydrousMarketedPhase 4none listed
NerandomilastMarketedPhase 4Ends 2032
CrisaboroleMarketedPhase 4Ends 2029
EnsifentrineMarketedPhase 3Ends 2031
IbudilastMarketedPhase 3none listed
DifamilastMarketedPhase 3Ends 2036
TranimilastStoppedPhase 3none listed
GSK-256066Went quietPhase 2none listed
TetomilastStoppedPhase 3none listed
LotamilastWent quietPhase 2none listed

12 of 26 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A7
Route B7
Engaged4
Undetermined3
Total on the list21
Three companies on route A or B, with the route only
CompanyRoute
Boehringer IngelheimRoute B
Chiesi FarmaceuticiRoute A
AstraZenecaRoute B

The other 18 companies at PDE4B

In the product

21 companies in all; 18 are not named here, and no score is.

See the 21 companies at PDE4B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at PDE4B

Other targets in skin and connective tissue

Companies holding approvals at PDE4B